Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
MicroSynbio, officially known as Beijing Micro-structure Factory, is a leading synthetic biology company specializing in the sustainable production of polyhydroxyalkanoates (PHA) and other high-value bio-based chemicals. Founded in 2021 by Professor Chen Guoqiang of Tsinghua University, the company utilizes a proprietary "Next-Generation Industrial Biotechnology" (NGIB) platform based on engineered halophilic bacteria (Halomonas). This platform enables open, continuous, and non-sterile fermentation, which significantly reduces energy consumption and production costs compared to traditional biomanufacturing methods. MicroSynbio's product portfolio includes various types of PHA for applications in biodegradable plastics, medical devices, and animal nutrition, as well as specialty chemicals like 3-hydroxybutyrate and ectoine. The company operates large-scale manufacturing facilities and has secured significant funding from major venture capital firms to scale its sustainable biomanufacturing solutions globally.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Micro Synbio.